Aspen’s disposal of its European thrombosis business has helped the firm to slash its annual net debt by more than 50%.
The debt reduction has allowed the pharmaceutical manufacturer to reinstate dividends at R2.62 after scrapping payouts before the pandemic.
Alishia Seckam spoke to CEO Stephen Saad for more detail.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.